The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.
Identifieur interne : 002311 ( Ncbi/Merge ); précédent : 002310; suivant : 002312The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.
Auteurs : Anthony H V. Schapira [Royaume-Uni]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- MESH :
- chemical , toxicity : Antiparkinson Agents, Levodopa.
- drug effects : Blood-Brain Barrier.
- drug therapy : Parkinson Disease.
- physiology : Blood-Brain Barrier.
- Animals, Clinical Trials as Topic, Disease Models, Animal, Humans.
Abstract
Levodopa is the 'gold standard' drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective.
DOI: 10.1002/mds.22146
PubMed: 18781678
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002052
- to stream PubMed, to step Curation: 002052
- to stream PubMed, to step Checkpoint: 002048
Links to Exploration step
pubmed:18781678Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name><affiliation wicri:level="3"><nlm:affiliation>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom. a.schapira@medsch.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.22146</idno><idno type="RBID">pubmed:18781678</idno><idno type="pmid">18781678</idno><idno type="wicri:Area/PubMed/Corpus">002052</idno><idno type="wicri:Area/PubMed/Curation">002052</idno><idno type="wicri:Area/PubMed/Checkpoint">002048</idno><idno type="wicri:Area/Ncbi/Merge">002311</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name><affiliation wicri:level="3"><nlm:affiliation>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom. a.schapira@medsch.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (toxicity)</term><term>Blood-Brain Barrier (drug effects)</term><term>Blood-Brain Barrier (physiology)</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Humans</term><term>Levodopa (toxicity)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood-Brain Barrier</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Blood-Brain Barrier</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the 'gold standard' drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18781678</PMID><DateCreated><Year>2008</Year><Month>09</Month><Day>18</Day></DateCreated><DateCompleted><Year>2009</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>23 Suppl 3</Volume><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>S515-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22146</ELocationID><Abstract><AbstractText>Levodopa is the 'gold standard' drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective.</AbstractText><CopyrightInformation>(c) 2008 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schapira</LastName><ForeName>Anthony H V</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom. a.schapira@medsch.ucl.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22146</ArticleId><ArticleId IdType="pubmed">18781678</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002311 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002311 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:18781678
|texte= The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:18781678" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |